Entries |
Document | Title | Date |
20080200438 | Treatment of Autoimmune Diseases - Methods of treating various autoimmune diseases, such as multiple sclerosis, peripheral neuritis, optical neuritis, amylotrophic lateral sclerosis, and uveitis utilizing specific amino alcohol derivatives are provided herein. | 08-21-2008 |
20080207566 | Methods for the administration of amifostine and related compounds - The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration. | 08-28-2008 |
20080214506 | Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing - The present invention discloses a method of employing ion channel active compounds to delivery metabolism-enhancing molecules within the cell to promote rapid wound healing. It also develops a delivery kit for meperidine as a local anesthetic and wound healing accelerant for dental surgical use. And meperidine thus serves as a pattern for future design off novel wound healing compounds. | 09-04-2008 |
20080249070 | Cycloalkane-Containing Sphingosine 1-Phospate Agonists - The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P | 10-09-2008 |
20080275006 | Process for the Preparation and Isolation of Phosphatides - Process for the preparation of phosphatidylserine of formula | 11-06-2008 |
20080275007 | CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE - The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins. | 11-06-2008 |
20080275008 | Aminophosphonic acid derivative, salt thereof, and modulator of sip receptor - Aminophosphonic acid derivatives (e.g., 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonate monoester) are represented by the following general formula (1): | 11-06-2008 |
20090023687 | Method for Controlling Phytopathogenic Organisms - The present invention is directed to methods of protecting crops of useful plants against attack by phytopathogenic organisms as well as the treatment of crops of useful plants infested by phytopathogenic organisms comprising administering a combination of glyphosate and at least one fungicide to the plant or locus thereof. | 01-22-2009 |
20090029947 | Sphingosine-1-phosphate receptor agonist and antagonist compounds - The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family. | 01-29-2009 |
20090029948 | Organic Derivatives, Their Salts and Use for the Control of Phytopathogens - Organic compounds are described, which are capable of forming quaternary salts, quaternary salts thereof with a structure having general formula (I) and their use for the control of phytopathogen fungi. | 01-29-2009 |
20090036410 | Structured Phospholipids - A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of γ-linolenoyl, dihomo-γ-linolenoyl acid and arachidonoyl. | 02-05-2009 |
20090042840 | Phospholipids for Use in the Treatment of an Allergic Inflammatory Condition - A phospholipid comprising a diacyl-substituted phosphatidyl group and a pharmaceutical composition comprising such a phospholipid for use in treatment of an allergic inflammatory condition and a method for the treatment of an allergic inflammatory condition. The phospholipid is particularly a mixture of phospholipids known as pumactant. | 02-12-2009 |
20090054377 | COMPOSITIONS AND METHODS FOR SMOKING CESSATION - The invention discloses a method and a composition for smoking cessation or for promoting smoking cessation in individual smokers. The compositions described contain phosphatidic acid as the active ingredient. | 02-26-2009 |
20090062238 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN - Compounds and methods useful for preventing and treating pain, e.g., neuropathic pain, in a subject in need thereof are provided. The compounds can be “S1P modulating” agents that are capable of inducing a detectable change in S1P receptor activity. | 03-05-2009 |
20090118239 | Amorphous and crystalline forms of ibandronate disodium - Provided are amorphous and crystalline forms of ibandronate disodium, as well as processes for the preparation thereof. | 05-07-2009 |
20090131373 | PHOSPHOLIPID COMPLEXES OF CURCUMIN HAVING IMPROVED BIOAVAILABILITY - The present invention relates to novel phospholipids complexes of curcumin or extracts containing it having improved bioavailability. | 05-21-2009 |
20090137530 | Amine Compound and Use Thereof for Medical Purposes - A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. | 05-28-2009 |
20090143339 | METHODS USING PHOSPHATIDYLSERINE, LYSOPHOSPHATIDYLSERINE, AND/OR SALTS THEREOF TO INCREASE TESTOSTERONE LEVELS - Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels in subjects in need thereof are disclosed herein. The methods can be useful for subjects having age related decline in testosterone, exercise induced decline in testosterone, and/or hypogonadism. | 06-04-2009 |
20090176744 | Deuterated fingolimod - This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod. | 07-09-2009 |
20090176745 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 07-09-2009 |
20090186857 | Combretastatin A-4 Phosphate Prodrug Mono- and Di- Organic Amine Salts, Mono- and Di- Amino Acid Salts, and Mono- and Di- Amino Acid Ester Salts - Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4. | 07-23-2009 |
20090197838 | ANTIMICROBIAL N-HALOGENATED AMINO ACID SALTS - The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens. | 08-06-2009 |
20090281065 | Use of Lysophospholipids to Treat Inflammation - Phospholipids and lysophospholipids, more particular lysophospatidylcholine (LPC), known to be pro-inflammatory in certain amounts, are demonstrated to be useful in the prevention, the treatment or amelioration of the effects of inflammation. | 11-12-2009 |
20090306018 | Skin conditioner - Moisture retention ability of skin is improved and/or skin is protected or treated for another purpose by applying thereto a composition containing at least one of the following compounds: ethanolamine, 2-methoxyethylamine, O-phosphorylethanolamine, 2-ethylaminoethanol, diethanolamine, 2-dimethylaminoethanol, choline, 2-amino-2-hydroxymethyl-1,3-propanediol, noradrenalin, phenethylamine, ethylenediamine, taurine, phosphatidylethanolamine, N-(2-hydroxyethyl)acetoamide, 2-(methylamino)ethanol, 2-anilinoethanol, 2-(benzylamino)ethanol, 3-amino-1-propanol, 2-amino-1-butanol, putrescine, DL-pyroglutamic acid and triethanolamine. | 12-10-2009 |
20090318392 | BIOFLUID METABOLITE PROFILING AS A TOOL FOR EARLY PREDICTION OF AUTOIMMUNITY AND TYPE 1 DIABETES RISK - The invention concerns a method for diagnosing a child's susceptibility for developing type 1 diabetes by using a serum metabolite as biomarker. The invention concerns also a method for prevention of the onset of type 1 diabetes in a child. | 12-24-2009 |
20090325907 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT - To provide an amino phosphate derivative having an excellent sphingosine-1-phosphate (S1P) receptor modulatory action. | 12-31-2009 |
20100009937 | PESTICIDE FORMULATION WITH STREAMING BIREFRINGENCE - A pesticide composition exhibiting streaming birefringence and methods for making the pesticide composition are disclosed. In one embodiment, the pesticide composition comprises an active ingredient and a surfactant adjuvant. | 01-14-2010 |
20100048514 | USE OF PHOSPHOLIPIDS FOR WOUND HEALING - The present invention provides a phospholipid and a pharmaceutical composition comprising a phospholipid for use in the treatment of a wound by inducing hyaluronic acid secretion; and a method of treating a wound comprising the application of a phospholipid thereto. | 02-25-2010 |
20100048515 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders - Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided. | 02-25-2010 |
20100056484 | DIETARY SUPPLEMENTAL COMPOSITION EFFECTIVE FOR ENHANCING COGNITIVE PERFORMANCE, ELEVATING MOOD AND REDUCING OXIDATIVE STRESS - A dietary supplemental composition composed of Acetyl-L-Carnitine, Phosphatidylserine, L-Alpha-Glycerylphosphorylcholine, fish oils including Docosahexaenoic acid, Alpha Lipoic Acid, and optionally Eicosapentaenoic acid, and which in combination has been demonstrated to be effective in increasing cognitive performance, elevating mood and decreasing oxidative stress levels in mammals. | 03-04-2010 |
20100069335 | Prevention and Treatment of Ophthalmic Complications of Diabetes - An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer. Most preferably, the metal chelator is EDTA or a salt of EDTA, and the transport enhancer is methylsulfonylmethane (MSM). The formulation may be in a form suitable for application to the eye itself, for example, in the form of eye drops. | 03-18-2010 |
20100081636 | METHOD FOR THE NEMATOCIDAL TREATMENT OF PLANTS USING EUGENOL AND/OR LECITHIN(S) AND/OR DERIVATIVES THEREOF - The invention relates to a method for the nematocidal treatment of horticulture plants, that comprises applying a composition containing a combination of lecithin(s) and/or derivative(s) thereof and of one or more terpenes or salts thereof acceptable in the food industry, or a mixture thereof. | 04-01-2010 |
20100087400 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof - The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions. | 04-08-2010 |
20100130449 | Use of Tri-Substituted Glycerol Compounds for the Treatment of Radiation Injuries - The present invention relates to the use of a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention and/or treatment of radiation injuries. Furthermore, the invention relates to in vitro corresponding methods for preventing or treating of radiation damage or injury in one or more cells comprising contacting said cells with a medicament as defined in the invention. | 05-27-2010 |
20100137256 | Device and Method for Treating Human Body - A method for contouring the body by destroying adipose tissue is disclosed. This method can reduce the circumference of the treated area, improve skin contour irregularities and smooth the appearance of the skin surface. The method is also used as a body treatment before and after a liposuction procedure. | 06-03-2010 |
20100137257 | METHOD FOR ALLEVIATING PAIN USING SPHINGOSINE-1-PHOSPHATE AND RELATED COMPOUNDS, AND ASSAYS FOR IDENTIFYING SUCH COMPOUNDS - Methods for alleviating pain comprising administering to a subject sphingosine-1-phosphate, functional fragments and derivatives thereof, and other compounds, and assays for identifying such compounds. | 06-03-2010 |
20100160258 | Bicyclic aryl sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
20100160259 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage | 06-24-2010 |
20100160260 | TRBD-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity - The present invention embraces compounds selected for interacting with the T-pocket of telomerase and use thereof for modulating the activity of telomerase and preventing or treating diseases or conditions associated with telomerase. | 06-24-2010 |
20100168068 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY - The invention provides novel compounds of formulae I and II: | 07-01-2010 |
20100173874 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear - The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus. | 07-08-2010 |
20100222305 | COMPLEXES OF PHOSPHATE DERIVATIVES - There is provided a composition comprising the reaction product of: a) one or more phosphate derivatives of one or more hydroxylated actives; and b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids. | 09-02-2010 |
20100249074 | BENZYL-CYCLOALKYL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS - Sphingosine- | 09-30-2010 |
20100261680 | HERBICIDES CONTAINING SUBSTITUTED THIEN-3-YL-SULPHONYLAMINO(THIO)CARBONYL-TRIAZOLIN(ETHI)ONES - The invention relates to herbicidal compositions, their preparation, and their use for controlling unwanted vegetation. The compositions include an effective amount of an active compound combination that includes: | 10-14-2010 |
20100267675 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators - The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y. | 10-21-2010 |
20100267676 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS - Gamma-amino-butyric acid derivatives that are GABA | 10-21-2010 |
20100292191 | Alkylene Oxide Adducts of Oligosaccharides - The invention is related to alkylene oxide adducts of oligosaccharides, obtained by a process comprising alkoxylating at least one water-soluble oligosaccharide in aqueous solution at a temperature in the range of 90 to 160° C. The compounds are useful as adjuvants in agrochemical compositions. | 11-18-2010 |
20100298273 | LIPID MIXTURE FOR INFANT NUTRITION - The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof. | 11-25-2010 |
20100317626 | The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD - The present invention is directed to the use of (3-Amino-2-fluoropropyl)phosphinic acid or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of non-erosive reflux disease (NERD). | 12-16-2010 |
20100317627 | Treatment of HCV Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV). | 12-16-2010 |
20100323991 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES - The invention provides a method of treating a disease or condition mediated by vascular hyperpermeability in an animal. The method comprises administering an amount of a danazol compound effective to inhibit vascular hyperpermeability and an amount of a second drug effective to treat the disease or condition. The invention further provides a method of inhibiting vascular hyperpermeability when it is a side effect caused by administration of a drug to, or another treatment of, an animal. The method comprises administration of an amount of a danazol compound effective to inhibit the vascular hyperpermeability. The invention also provides a method of modulating the cytoskeleton of endothelial cells in an animal comprising administering an amount of a danazol compound and an amount of a second drug effective to modulate the cytoskeleton. The present invention also relates to pharmaceutical compositions and kits comprising a danazol compound and a second drug. | 12-23-2010 |
20110015159 | METHODS OF INHIBITING VASCULAR PERMEABILITY AND APOPTOSIS - Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. | 01-20-2011 |
20110028438 | MEDICAL USE OF 3-2,2,2-TRIMETHYLHYDRAZINIUM PROPIONATE SALTS. - The present invention relates to highly effective treatment of ischemic heart disease with 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate, and 3-(2,2,2-trimethylhydrazinium) propionate dihydrogen phosphate. | 02-03-2011 |
20110034419 | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease - Disclosed are methods of diagnosing cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of predicting cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of identifying subjects at risk of developing cardiovascular disease comprising measuring sphingolipids. | 02-10-2011 |
20110034420 | NOVEL CRYSTALLINE FORM B OF (2R)-(3-AMINO-2-FLUOROPROPYL)PHOSPHINIC ACID - The present invention relates to a novel crystalline form of (2R)-(3-amino-2-fluoropropyl)phosphinic acid, the present invention is also directed to the use of the crystalline form for the treatment of gastrointestinal disorders as well as to a pharmaceutical compositions comprising the same and a process for the preparation of the crystalline form. | 02-10-2011 |
20110053894 | Broad Spectrum Antiviral and Methods of Use - A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided. | 03-03-2011 |
20110059923 | NOVEL PHOSPHATE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, A PRODUCTION METHOD THEREFOR AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS CONTAINING THE SAME AS AN ACTIVE COMPONENT - The present invention relates to a novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders which contains the same as an active component. The novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof according to the present invention can beneficially be used to prevent and treat central nervous system disorders since it exhibits an equivalent biological and pharmacological activity to venlafaxine and salts thereof which are known in the field, it has very little toxicity, and, in particular, it is outstandingly soluble in water as compared with prior-art venlafaxine derivatives. | 03-10-2011 |
20110077223 | CHIMERIC PROMOTERS FOR USE IN PLANTS - The present invention provides polynucleotide molecules useful for expressing transgenes in plants. The present invention also provides expression constructs containing the polynucleotide molecules useful for expressing transgenes in plants. The present invention also provides transgenic plants and seeds containing the polynucleotide molecules useful for expressing transgenes in plants. | 03-31-2011 |
20110092466 | Method for Protecting Soybeans from Being Infected by Fungi - Method for protecting soybean plants from being infected by harmful fungi, wherein the soybean plants, their seed or the soil is treated with a fungicidal effective amount of a synergistically active combination comprising
| 04-21-2011 |
20110124604 | PHOSPHOLIPID RECEPTORS AS TARGETS FOR ENHANCING DRUG PERMEABILITY TO SELECTED TISSUES - A method for enhancing drug delivery to the brain in neurological disorders using lysophosphatidic acid (LPA) and sphingosine I phosphate (S1P) is herein described. Specifically, the permeability properties of LPA and S1P allow for a highly controlled and transient disruption of blood-brain barrier permeability. Thus these phospholipids can be used for delivering a wide variety of therapeutic, prophylactic or diagnostic agents to the brain. | 05-26-2011 |
20110124605 | Use of an S1P Receptor Agonist - The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy. | 05-26-2011 |
20110144063 | GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS - The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations. | 06-16-2011 |
20110152221 | PAK1 Agonists and Methods of Use - The present invention is directed to Pak1 agonists and methods of use. | 06-23-2011 |
20110166108 | METHODS OF USE RELATED TO XEROSTOMIA - The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and neck cancer. | 07-07-2011 |
20110183941 | Herbicide consisting of a glyphosate formulation containing a surfactant consisting in a branched alkyl alcohol polyethoxylated or polypropoxylated and a mixture of alkylamines - Linear alkyl amine polyethoxylated containing in the alkyl chain 16 to 20 carbon atoms are worldwide used as surfactants for herbicides based on glyphosate. | 07-28-2011 |
20110183942 | Methods and Compositions for Treating Alzheimer's Disease - A method is disclosed for inhibiting the build-up of amyloid plaques in the brain of a patient with at least one risk factor for, or a diagnosis of, Alzheimer's Disease by administering to the patient an amount of one or more compounds effective to inhibit the phosphorylative activity of eEF2K, thereby inhibiting amyloid plaque deposition. | 07-28-2011 |
20110190238 | MODIFICATIONS OF SOLID 3-SN-PHOSPHOGLYCERIDES - Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A | 08-04-2011 |
20110195936 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 08-11-2011 |
20110195937 | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF - Novel oxidized thiophospholipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. Exemplary oxidized thiophospholipid according to embodiments described herein have the formula: | 08-11-2011 |
20110257132 | CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE - The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins. | 10-20-2011 |
20110257133 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage. | 10-20-2011 |
20120035139 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS - Gamma-amino-butyric acid derivatives that are GABA | 02-09-2012 |
20120065172 | NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS - A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. | 03-15-2012 |
20120101068 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT - Provided are diphenyl sulfide derivatives which have excellent S1P3 antagonistic activity and are useful as drugs. Intensive studies have been made for the purpose of creating a compound having S1P3 antagonistic activity. As a result of the intensive studies, it has been found that diphenyl sulfide derivatives represented by general formula (1) have excellent S1P3 antagonistic activity. In general formula (1), R | 04-26-2012 |
20120115816 | COMPATIBILIZED ELECTROLYTE FORMULATIONS - The invention includes aqueous compatibilized pesticidal formulations and methods of making them. In typical embodiments, formulations comprise a first electrolytic pesticide and a second electrolytic pesticide, and about 30 to about 300 g/L of at least one alkyl polyglycoside. The invention also includes methods of preparing pesticidal formulations to increase the concentration of the electrolytic pesticides. The invention also includes storage and transport systems containing formulation embodiments. The invention also includes methods inhibiting pests. | 05-10-2012 |
20120122821 | STEROID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS - Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use. | 05-17-2012 |
20120135966 | USE OF GLYPHOSATE FOR DISEASE SUPPRESSION AND YIELD ENHANCEMENT IN SOYBEAN - The present invention discloses methods for prevention and prophylactic treatment of plant diseases by application of glyphosate to a plant in need of treatment. In certain embodiments, soybean plants in need of treatment at vegetative and reproductive growth stages prior to or subsequent to infection, may be treated with glyphosate in order to prevent infection or suppress disease development, symptomatology, and yield loss. Application of a fungicide (e.g. a strobilurin fungicide such as pyraclostrobin or picoxystrobin) together with glyphosate, is also contemplated. Soybean diseases that may be treated in this manner include Soybean Sudden Death, Brown Stem Rot, Stem Canker, and Charcoal Rot, among others. | 05-31-2012 |
20120142642 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 06-07-2012 |
20120142643 | CLONIDINE AND GABA COMPOUNDS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 06-07-2012 |
20120165297 | SYNERGISTIC COMBINATION OF A GLYPHOSATE COMPOUND AND DMITS - A synergistic antimicrobial composition containing a glyphosate compound and diiodomethyl-p-tolylsulfone is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition. | 06-28-2012 |
20120190648 | FLUORINATED CYCLOPROPANE ANALOGS OF GLUTAMIC ACID - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a mixture in all proportions of stereoisomers thereof, in particular a mixture of enantiomers, such as a racemic mixture, wherein R represents a (C | 07-26-2012 |
20120190649 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 07-26-2012 |
20120214771 | COMPOSITIONS FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins. | 08-23-2012 |
20120225848 | Antagonists of GABA-B Receptors to Enhance Neuronal Function, Learning and Memory - Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a GABAB antagonist, or a blocker of Kir3.2 potassium channels, is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications. | 09-06-2012 |
20120245129 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression. | 09-27-2012 |
20120264719 | DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR - S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile. | 10-18-2012 |
20120277194 | AMINOPROPANOL DERIVATIVES - Compounds of formula I: | 11-01-2012 |
20120277195 | PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS - A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 10-50% of Pracaxi oil, 15-40% of Patauá oil, 10-30% of Inaja oil, and 10-30% of one of more emollients. | 11-01-2012 |
20120283223 | CEREBRAL NERVE CELL NEOGENESIS AGENT - An objective of the present invention is to provide a new substance having a cerebral nerve cell neogenesis effect. Another objective is to provide a cerebral nerve cell neogenesis agent that is effective in treating and/or preventing neurological disorders utilizing the substance. With the present invention, a cerebral nerve cell neogenesis agent containing a plasmalogen as an active ingredient is provided. In particular, a preferable cerebral nerve cell neogenesis agent contains, as an active ingredient, a biological tissue (preferably, an avian tissue) extracted plasmalogen mainly including an ethanolamine plasmalogen and a choline plasmalogen. | 11-08-2012 |
20130059821 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors. | 03-07-2013 |
20130079308 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof - The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions. | 03-28-2013 |
20130079309 | Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists - The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation. | 03-28-2013 |
20130090312 | METHODS OF USE RELATED TO XEROSTOMIA - The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and neck cancer. | 04-11-2013 |
20130172297 | Treatment of Autoimmune Diseases - Disclosed is the use of a compound of formula I wherein X is O, S, SO or SO | 07-04-2013 |
20130203707 | Oxidized Lipid Compounds and Uses Thereof - Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. | 08-08-2013 |
20130217652 | SULFINYLBENZYL AND THIOBENZYL DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel thiobenzyl and sulfinylbenzyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-22-2013 |
20130261089 | DIPHENYL SULFIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT WHICH CONTAINS SAME AS ACTIVE INGREDIENT - [Problem] To provide a diphenyl sulfide derivative which is useful as a pharmaceutical product that has excellent S1P3 antagonist activity. | 10-03-2013 |
20130281409 | Myelin Sheath Fatty Acids that Resolve Neuroinflammation - Methods are provided for decreasing inflammatory disease in a subject by administering an effective dose of a lipid, fatty acid, or analog thereof. | 10-24-2013 |
20130296277 | Pharmaceutical Compositions for the Treatment of Parasitic Diseases, Cancer, or Skin Diseases by Topical Administration - The present invention relates to pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration and especially ointments for the treatment of leishmaniasis. The present invention further relates to the use of the present ointments for the treatment of parasitic diseases, cancer, or skin diseases and especially ointments for the treatment of leishmaniasis in both humans and animals. Specifically, the present invention relates to pharmaceutical compositions such as ointments and crèmes for the treatment of parasitic diseases, cancer, or skin diseases by topical administration comprising 0.1 to 20 weight %, preferably 0.1 to 10 weight %, more preferably 0.1 to 7 weight %, most preferably 0.5 to 5 weight %, of the pharmaceutical composition oleyl phosphocholine as an active ingredient. | 11-07-2013 |
20130303490 | Inhibitors of HIV Infections and uses thereof - The invention relates to compounds which are agonists of at least one receptor selected from S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 receptors, for use in methods for treating HIV infections in humans or animals. | 11-14-2013 |
20130345177 | Oleyl Phosphocholine for the Treatment of Mycosis - The present invention relates to the use of oleyl phosphocholine (C18:1-PC), or OlPC,for the treatment of mycosis, and especially for the treatment of mycosis such as mycosis caused by pathogens belonging to a genus selected from the group consisting of | 12-26-2013 |
20140057878 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 02-27-2014 |
20140066409 | CYCLOHEXANE COMPOUNDS AND THEIR USE AS ANTIBIOTICS - The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic. | 03-06-2014 |
20140094437 | HIGH ALCOHOL CONTENT FOAMING COMPOSITIONS - This invention relates to a “high lower alcohol content”(>40% v/v of a C | 04-03-2014 |
20140113883 | Therapeutic micro nutrient composition for lipolysis and sclerosis - An improved formulation and method for the removal of subcutaneous fat deposits in a human in need of such treatment. It also induces an inflammatory reaction which treats disorders of tissue adhesion which often accompany subcutaneous fat deposits or are created in the process of removal of subcutaneous fat deposits. This inflammatory reaction also limits the extent of the effect of the injected medication to a localized area. A lecithin and aqueous glucose and sodium chloride based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. Additionally, a program based approach to the treatment of subcutaneous fat deposits which includes injections of this formulation, application of compression garments, diet modification, and exercise is described. The formulation is characterized in that it comprises an adjustable acidifying agent to set pH, an antioxidant, a sclerosing agent, and a stabilizer. It is further characterized in that it includes liposomes, and that the components of these liposomes are therapeutic in the treatment of several human ailments. It is also efficacious in the treatment of striae albicantes, striae atrophicae, cellulite, and decreased skin turgor. | 04-24-2014 |
20140148415 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage. | 05-29-2014 |
20140155355 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY - The invention provides novel compounds of formulae I and II: | 06-05-2014 |
20140179636 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 06-26-2014 |
20140187516 | DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR - S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile. | 07-03-2014 |
20140194392 | DRUG SCREENING METHOD - A drug screening method is disclosed. The drug screening method includes steps of screening a compound library to obtain a first group of compounds capable of binding to a wild type target; screening the first group of compounds to obtain a second group of compounds capable of binding to a mutant site of a mutant target; analyzing characteristics of binding sites of the wild type target and the mutant type target to obtain physico-chemical properties of the binding sites; identifying a candidate from the second group of compounds according to the physico-chemical properties of the binding site; and performing a bio-assay on inhibitory activity of the candidate. | 07-10-2014 |
20140206652 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 07-24-2014 |
20140213557 | Active Compound Combinations - The present invention relates to novel active compound combinations comprising, firstly, a known herbicide selected from the group consisting of glyphosate, glufosinate and glufosinate-ammonium and, secondly, at least one known fungicidally active compound, which combination is highly suitable for controlling unwanted phytopathogenic fungi, in particular soya bean rust. Particular preference is given to using these mixtures on transgenic plants resistant to the herbicides mentioned. | 07-31-2014 |
20140235591 | BICYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 08-21-2014 |
20140296187 | METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF - A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention. | 10-02-2014 |
20140329774 | INJECTABLE COMPOSITION CONTAINING PHOSPHATIDYLCHOLINE DEVOID OF SODIUM DEOXYCHOLATE AND PREPARING METHOD THEREOF - The present invention includes an injectable composition containing phosphatidylcholine including phosphatidylcholine; ethanol; propylene glycol and/or benzyl alcohol; polysorbate and/or macrogol 15 hydroxystearate; and a balance of water or water for injection, and a preparing method thereof. An injectable composition of the present invention includes no sodium deoxycholate, which is carcinogenic, and therefore a safer injectable composition of phosphatidylcholine can be prepared. | 11-06-2014 |
20150038467 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHOSPHATIDYLSERINE AND CURCUMIN - The present invention describes and claims stable pharmaceutical compositions and/or food supplements based on phosphatidylserine (PS) and curcumin, which are consequently devoid of degradation products, for use in the prevention and treatment of disorders associated with brain aging, and in the prevention and treatment of osteoporosis and/or osteoarthritis. | 02-05-2015 |
20150038468 | ESTROGEN ANTAGONISTS AS TREATMENTS FOR SCLEROSING DISORDERS - The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions. | 02-05-2015 |
20150045328 | DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to aryl oxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 02-12-2015 |
20150051176 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors | 02-19-2015 |
20150057253 | ALKYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 02-26-2015 |
20150065467 | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES OR DISORDERS OF THE EYE - In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. | 03-05-2015 |
20150080347 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 03-19-2015 |
20150080348 | Compositions And Methods For Amelioration And Prevention Of Drug-Induced Toxicity - Pharmaceutical compositions including combinations of protective agents selected from isosilybin B, methylsulfonylmethane (MSM), phosphatidylcholine, cysteine (Cys), seleno-cysteine (Se-Cys), ribose-cysteine (RibCys), N-acetylcysteine (NAC), N-acetylcysteine-amide (AD4), methionine (Met) and S-adenosylmethionine (SAM) for reducing and/or preventing drug-induced toxicity, such as acetaminophen-induced toxicity. The compositions may be formulated with or without acetaminophen, and accordingly may be used as safe formulations of acetaminophen with reduced risk of causing liver damage, or as an antidote for the treatment of acetaminophen overdose. Methods for treating acetaminophen intoxication. | 03-19-2015 |
20150148316 | LIPID MIXTURE FOR INFANT NUTRITION - The subject invention includes a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said phospholipid and uses thereof. | 05-28-2015 |
20150290225 | COMPOSITIONS AND METHODS OF USING SAME - The present disclosure provides compositions and methods for the treatment of disease and/or disorders of this skin. | 10-15-2015 |
20150307530 | NOVEL MUCOLYTIC AGENTS - Provided is a method of liquefying mucus from mucosal surfaces by administering compounds containing a phosphine group. | 10-29-2015 |
20150335665 | USE OF ETHANOLAMINE PHOSPHATE - A method of inhibiting oxidative stress to a cell that includes contacting a cell with an effective amount of ethanolamine phosphate. An animal cell function enhancer containing ethanolamine phosphate (EP) as an active ingredient. The presence of the ethanolamine phosphate enhances the function of the animal cell even in the absence of serum and growth factors. | 11-26-2015 |
20160038518 | METHODS FOR TREATING PSORIASIS AND VASCULAR INFLAMMATION - Described are methods of decreasing vascular inflammation in a subject suffering from a chronic autoimmune or chronic inflammatory disease by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg/day to about 160 mg/day, optionally administered in two daily sub-doses. Also described are methods of treating inflammation associated with an implant (e.g., a breast implant) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg/day to about 160 mg/day, optionally administered in two daily sub-doses. Further described are methods of treating psoriasis (e.g., active plaque psoriasis) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 80 mg/day to about 160 mg/day, optionally administered in two daily sub-doses. | 02-11-2016 |
20160075726 | TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL - The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n=6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine. | 03-17-2016 |
20160136189 | METHODS FOR TREATING AND PREVENTING PROSTATE CANCER BONE METASTASES - Methods for treating a subject having a prostate cancer bone metastasis are disclosed. Methods for prophylactically treating a subject at risk of developing a prostate cancer bone metastasis are also disclosed. The methods for treating a subject having, or at risk of developing, a prostate cancer bone metastasis may include administering a prostatic acid phosphatase inhibiting agent to the subject. The methods for treating a subject having, or at risk of developing, a prostate cancer bone metastasis may also include administering a phosphonic acid to the subject. Further, the phosphonic acid may include a benzylaminophosphonic acid, such as [phenyl[(phenylmethyl)amino]methyl]-phosphonic acid). | 05-19-2016 |
20160158182 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE DONOR - The present invention relates to compositions comprising a 4-nitrooxybutan-1-ol alkyl ester as nitric oxide donor. More specifically, the invention relates to compositions comprising 4-nitrooxybutan-1-ol alkyl ester as a nitric oxide donor and an ophthalmic drug, useful in controlling elevated intraocular pressure associated with glaucoma or ocular hypertension associated with other diseases or conditions. The invention is also directed to methods of controlling intraocular pressure utilizing said compositions. | 06-09-2016 |
20160185710 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS - β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types. | 06-30-2016 |
20160193147 | VESICLES | 07-07-2016 |
20160193236 | GOLD(I) COMPLEXES WITH T-BUTYL PHOSPHINE AND DIALKYL DITHIOCARBAMATE LIGANDS | 07-07-2016 |
20160194351 | Progesterone Phosphate Analogs and Uses Related Thereto | 07-07-2016 |
20160374974 | SERINE GLYCEROPHOSPHOLIPID PREPARATION AND METHOD FOR TREATMENT OF SEIZURES - A preparation for treatment and/or prevention of seizures comprising a non-mammalian derived mixture of serine glycerophospholipids (PS) conjugates, wherein the mixture comprises (a) Eicosapentaenoic acid (EPA) conjugated to PS and (b) Docosahexaenoic acid (DHA) conjugated to PS, and methods of treatment of seizures with same. | 12-29-2016 |
20160375043 | CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS - The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and dieases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition. | 12-29-2016 |
20170232021 | COMPOSITIONS AND METHODS OF USING SAME | 08-17-2017 |
20220135603 | OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE - A novel compound has pharmacological activities comparable to those of Nahlsgen and is storable excellently stably. The compound can be produced by a method according to the present invention for producing an optically active 2-amino-phosphonoalkanoic acid salt. In the method, a starting material DL-2-amino-phosphonoalkanoic acid represented by Formula (1) or a hydrate thereof is reacted with an optically active basic compound other than an optically active lysine, to give a diastereomeric salt mixture including a first salt (including a hydrate salt) between a D-2-amino-phosphonoalkanoic acid represented by Formula (1-1) and the optically active basic compound, and a second salt (including a hydrate salt) between an L-2-amino-phosphonoalkanoic acid represented by Formula (1-2) and the optically active basic compound. The diastereomeric salt mixture is fractionally crystallized to isolate one of the first and second diastereomeric salts. | 05-05-2022 |